Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    15867204 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Pegylated liposomal doxorubicin;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Cyclophophamide;   Drug: Vincristine;   Drug: Prednisone
2 Terminated Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: MK2206
3 Recruiting Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Rituximab+mVPDL
4 Active, not recruiting Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
Conditions: Lymphoma, Non-Hodgkin;   Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Ondansetron;   Drug: Dexamethasone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Ifosfamide;   Drug: Mesna (IV);   Drug: Mesna (oral);   Drug: Carboplatin;   Drug: Etoposide;   Drug: Rituximab;   Other: PET Scan
5 Completed ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide;   Procedure: autologous stem cell transplantation
6 Completed R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Intervention: Drug: Darbepoetin alfa
7 Terminated ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide
8 Completed ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
Condition: Diffuse Large-Cell Lymphoma
Interventions: Drug: rituximab;   Drug: doxorubicin;   Drug: cyclophosphamide

Indicates status has not been verified in more than two years